Etodolac

Introduction Overview

Generic Name

etodolac

Brand Name

Lodine, Lodine XL

Dosage Form

Immediate-release tablets, Extended-release tablets

Drug Class

Nonsteroidal anti-inflammatory drugs (NSAIDs)

Pharmacokinetics

Absorption:
Etodolac exhibits rapid and extensive absorption after oral administration, with peak plasma concentrations typically occurring within 1 to 2 hours for immediate-release formulations. The bioavailability is high, reflecting efficient gastrointestinal uptake. Food intake can moderately delay the time to peak concentration without significantly affecting overall absorption. Extended-release formulations are designed to provide a prolonged plasma concentration, allowing once-daily dosing and maintaining therapeutic levels over 24 hours. Clinical studies have demonstrated that steady-state concentrations are achieved within 3 days of consistent dosing.

Distribution:
Etodolac is widely distributed throughout body tissues and fluids with a moderate volume of distribution approximating 15-20 liters. The drug exhibits approximately 99% plasma protein binding, primarily to albumin, which is important in its pharmacodynamics and potential drug interactions. The high protein binding limits free drug concentrations but facilitates a sustained anti-inflammatory effect. Etodolac can penetrate synovial fluid, contributing to its efficacy in treating arthritis. Distribution is not significantly altered in mild to moderate hepatic impairment but should be monitored in severe cases.

Metabolism:
Etodolac undergoes extensive hepatic metabolism predominantly via cytochrome P450 enzymes, particularly CYP2C9 and CYP3A4 isoforms. The primary metabolic pathways include hydroxylation and subsequent conjugation forming inactive metabolites. These metabolites are ultimately excreted renally. Genetic polymorphisms affecting CYP2C9 can influence etodolac metabolism rates, potentially altering drug plasma levels and efficacy. Drug interactions involving enzyme inducers or inhibitors can modulate the metabolism and clearance of etodolac.

Elimination:
The elimination half-life of etodolac ranges from 7 to 12 hours for immediate-release forms, supporting multiple daily dosing, whereas extended-release forms have prolonged half-lives facilitating once-daily administration. Approximately 80% of the administered dose is recovered in the urine mainly as metabolites, and about 20% is excreted via feces. Renal excretion is the primary elimination route, making renal function an important consideration. Dose adjustment may be necessary in significant renal impairment to prevent accumulation and toxicity. The drug does not significantly accumulate during repeated dosing due to its balanced metabolic and excretory pathways.

Dosage Forms

Available Dosage Forms:
- Oral Immediate-Release Tablets: 200 mg, 300 mg, 400 mg, 500 mg
- Oral Extended-Release Tablets (Lodine XL): 400 mg, 500 mg, 600 mg, 800 mg, 1000 mg

Dosages for Adults and Adolescents:
- Osteoarthritis and Rheumatoid Arthritis:
* Immediate Release: Initial 300 mg orally 2 to 3 times daily or 400-500 mg orally twice daily; maintenance doses as low as 600 mg/day; maximum 1000 mg/day.
* Extended Release: 400 mg to 1000 mg orally once daily.
- Acute Pain:
* Immediate Release: 200 mg to 400 mg orally every 6 to 8 hours; maximum 1000 mg/day.

Specific Patient Populations:
- Pediatric (Juvenile Rheumatoid Arthritis, 6-16 years):
* 20-30 kg: 400 mg once daily (extended release)
* 31-45 kg: 600 mg once daily (extended release)
* 46-60 kg: 800 mg once daily (extended release)
* >60 kg: 1000 mg once daily (extended release)
- Adolescents 17-18 years: 400 mg to 1000 mg once daily (extended release)
- Use in pregnancy is contraindicated especially beyond 20 weeks gestation due to risks of fetal cardiovascular and renal complications.
- Not approved for children under 6 years of age.
- Dose adjustments should be considered in patients with renal or hepatic impairment, following clinical judgment.

Clinical administration instructions emphasize swallowing extended-release tablets whole without crushing or chewing. Dose titration should be individualized based on therapeutic response and tolerability, with monitoring for adverse effects during long-term use.

Mechanism Of Action

Etodolac selectively inhibits cyclooxygenase (COX) enzymes, primarily COX-2, leading to reduced synthesis of prostaglandins, which are key mediators of inflammation, pain, and fever. By limiting prostaglandin production, etodolac diminishes the inflammatory response, alleviating symptoms associated with arthritis and acute pain.

At the molecular level, etodolac binds competitively to the active site of COX enzymes, blocking the conversion of arachidonic acid to prostaglandin H2, the precursor of various prostaglandins and thromboxanes. Its relative COX-2 selectivity contributes to a potentially improved gastrointestinal safety profile compared to non-selective NSAIDs, although gastrointestinal risks remain.

Cellular pathways affected by etodolac include the suppression of inflammatory cell activation and migration through decreased prostaglandin-mediated signaling. Additionally, etodolac impacts sensitization of nociceptors, reducing pain transmission. This mechanism supports its efficacy in managing both acute pain and chronic inflammatory conditions such as osteoarthritis and rheumatoid arthritis.

Clinical implications of etodolac’s mechanism include reduced inflammation and pain without significant interference with platelet function, though bleeding risks persist. Comparative studies have shown etodolac's clinical benefits are similar to other NSAIDs, with some evidence suggesting lower gastrointestinal toxicity due to its COX-2 preferential inhibition. Ongoing research evaluates its precise COX isoform selectivity and long-term safety profile relative to other anti-inflammatory agents.

Pharmacological Actions

Nonsteroidal anti-inflammatory action through inhibition of prostaglandin synthesis
Analgesic effects for relief of mild to moderate pain
Antipyretic properties reducing fever
Selective inhibition of cyclooxygenase-2 (COX-2) enzyme
Reduction of inflammation in synovial joints in osteoarthritis and rheumatoid arthritis
Decreased sensitization of peripheral nociceptors to inflammatory mediators
Minimal impact on platelet aggregation compared to non-selective NSAIDs
Modulation of inflammatory cell recruitment and activation
Prolonged anti-inflammatory effect with extended-release formulations
Possible reduction in gastrointestinal toxicity relative to nonselective NSAIDs due to COX-2 preference
Renal prostaglandin synthesis inhibition impacting fluid retention and renal function
Potential interaction with hepatic enzymes altering metabolism of concomitant drugs
Capable of crossing into synovial fluid to exert localized effects
Therapeutic plasma concentrations achievable with oral dosing

Therapeutic Or Clinical Uses

Management of osteoarthritis symptoms including joint pain and inflammation
Treatment of rheumatoid arthritis for control of pain and swelling
Relief of acute mild to moderate pain from various etiologies
Management of juvenile rheumatoid arthritis in pediatric patients aged 6 years and older
Reduction of inflammation and improved joint mobility in chronic arthritis
Symptomatic treatment to improve quality of life in arthritis patients
Alternative NSAID choice in patients requiring COX-2 selective activity
Use in patients intolerant to other anti-inflammatory drugs
Adjunctive therapy in multi-modal pain management strategies
Treatment of musculoskeletal pain and soft tissue injuries
Off-label use guided by clinical judgment per inflammatory or pain conditions
Prevention of progression of inflammatory symptoms with long-term therapy
Use in outpatient and inpatient settings for inflammatory disorders
Management of postoperative pain in specific clinical contexts as advised
Therapeutic option for patients unsuitable for corticosteroid use

Side Or Adverse Effects

Gastrointestinal disturbances: nausea, vomiting, abdominal pain, indigestion, diarrhea, constipation, flatulence
Gastrointestinal bleeding including occult and overt blood loss
Dizziness and headache, occasionally accompanied by fatigue
Rashes and other dermatologic reactions including rare severe skin reactions
Tinnitus and other alterations in auditory perception
Renal impairment including reduced urine output and edema
Liver dysfunction signs: nausea, jaundice, elevated liver enzymes
Anemia potentially due to occult bleeding
Hypersensitivity reactions such as rash, urticaria, and rarely anaphylaxis
Fluid retention and peripheral edema
Increased risk of cardiovascular events: myocardial infarction and stroke
Respiratory reactions including asthma exacerbation
Potential alterations in laboratory parameters affecting kidney and liver function tests
Photosensitivity reactions leading to increased risk of sunburn
Rare severe adverse events such as Stevens-Johnson syndrome and toxic epidermal necrolysis

Precautions

Use lowest effective dose for shortest duration to minimize adverse effects
Monitor patients with preexisting cardiovascular disease for fatal heart attack or stroke risk
Avoid use before or after coronary artery bypass graft surgery due to increased cardiovascular risk
Cautious use in patients with history of gastrointestinal ulceration or bleeding
Regular monitoring of renal and hepatic function during long-term therapy
Avoid concomitant use with other NSAIDs or aspirin unless directed by physician
Avoid alcohol consumption to reduce gastrointestinal bleeding risk
Use caution in patients with hypertension, diabetes, or fluid retention
Careful assessment in elderly patients who are at increased risk of adverse reactions
Advise patients to report signs of bleeding, shortness of breath, or allergic reactions immediately
Avoid use during the last trimester of pregnancy due to fetal risks
Inform patients about potential photosensitivity and recommend sun protection measures
Evaluate drug interactions carefully especially with anticoagulants, diuretics, and corticosteroids
Titrate doses cautiously in pediatric populations and those with hepatic/renal impairment
Educate patients about adherence to dosing instructions to prevent overdose

Warnings

Increased risk of fatal cardiovascular thrombotic events including heart attack and stroke
Contraindicated in perioperative setting of coronary artery bypass graft (CABG) surgery
Potentially fatal gastrointestinal bleeding, ulceration, and perforation which may occur without warning
Not to be used in patients with known hypersensitivity to etodolac or other NSAIDs
Risk of severe hypersensitivity reactions including anaphylaxis in aspirin-sensitive patients
May cause serious skin adverse reactions such as Stevens-Johnson syndrome
Pregnancy category contraindication particularly in the third trimester due to fetal harm
Possible severe hepatic adverse effects including liver failure
Use with caution in patients with impaired renal function or heart failure
Concomitant use with anticoagulants may enhance bleeding risk
May interfere with platelet function resulting in prolonged bleeding time
Avoid combining with other nephrotoxic drugs to prevent kidney damage
Patients should avoid driving or operating machinery if dizziness or somnolence occurs
Warning about potential masking of infection symptoms due to anti-inflammatory effects
Risk of anemia secondary to occult gastrointestinal blood loss

Contraindication

Hypersensitivity to etodolac, aspirin, or other NSAIDs
History of asthma, urticaria, or other allergic-type reactions after NSAIDs or aspirin use
Active or history of recurrent gastrointestinal bleeding or ulceration
Perioperative use during coronary artery bypass graft (CABG) surgery
Pregnancy, especially during the third trimester
Severe hepatic or renal impairment
Patients with bleeding disorders or clinically significant coagulopathy
Known hypersensitivity to any component of the formulation
Use in pediatric patients under 6 years of age
Patients with severe heart failure or uncontrolled hypertension
Concurrent use with other NSAIDs except under medical supervision
History of severe skin reactions to NSAIDs
Known cardiovascular disease with unstable angina or recent myocardial infarction
Patients with severe dehydration due to risk of renal toxicity
Concomitant use with medications that may cause serious interaction without appropriate monitoring

Drug Interactions

Concomitant use with anticoagulants (e.g., warfarin) increases bleeding risk
Interaction with lithium leading to increased lithium toxicity due to reduced renal clearance
Concurrent methotrexate therapy may increase methotrexate toxicity
Cyclosporine levels and nephrotoxicity may increase when combined with etodolac
Caution advised when used with corticosteroids due to additive gastrointestinal risk
Pharmacokinetic interaction with diuretics may reduce their efficacy
Potential reduction of antihypertensive effects of ACE inhibitors and beta-blockers
Use with selective serotonin reuptake inhibitors (SSRIs) may increase bleeding tendency
Antacids may impair absorption of etodolac if not administered separately
Drug interactions with other NSAIDs or aspirin may increase adverse effects
Enzyme inhibitors or inducers affecting CYP2C9 and CYP3A4 can alter etodolac metabolism
Potential enhanced neurotoxicity when combined with certain antidepressants
Avoid combination with nephrotoxic agents to reduce renal impairment risk
Drugs affecting platelet function combined with etodolac increase hemorrhage risk
Herbal supplements such as ginkgo biloba may potentiate bleeding risk when used with etodolac

Preparations Of The Drug

Immediate-release oral tablets available in 200 mg, 300 mg, 400 mg, and 500 mg strengths
Extended-release oral tablets (Lodine XL) in 400 mg, 500 mg, 600 mg, 800 mg, and 1000 mg strengths
Formulations designed for oral administration only
Extended-release formulation formulated for once-daily dosing to improve compliance
Available as prescription-only medication requiring medical supervision
Manufactured with specific coatings to enable extended-release properties
Packaging provided for both individual blister packs and multi-dose bottles
Storage guidelines recommend room temperature, protected from moisture and heat
No commercially available intravenous or topical formulations
Supply includes patient information leaflets detailing proper use and precautions
Preparation standards comply with FDA and pharmacopeial quality requirements
Available under brand names Lodine and Lodine XL with consistent bioavailability
Bulk formulations used for compounding are not standard due to safety considerations
Physical appearance varies by manufacturer but includes standard tablet shapes and imprints
Stability data supports a shelf life of typically 2 to 3 years under recommended storage